CNSY · Cerenome, Inc.
AI read · Good for CNSY
The AI's read
That gives Cerenome an early commercial foothold: its test business is earning revenue, and more insurers cover its tests. Broader coverage may help more cancer centers order them. But this is an early sales result, not proof of broad use. Medicare coverage is still being pursued, and the drug-trial update reports safety, not evidence that treatment works. The commercial progress leads.